

**AWARD NUMBER: W81XWH-15-1-0076**

**TITLE: Atypical Opioid Mechanisms of Control of Injury-Induced Cutaneous Pain by Delta Receptors**

**PRINCIPAL INVESTIGATOR: Dr. Gregory Scherrer**

**CONTRACTING ORGANIZATION: Stanford University  
Palo Alto, CA 94305**

**REPORT DATE: July 2017**

**TYPE OF REPORT: Annual**

**PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012**

**DISTRIBUTION STATEMENT:** Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved  
OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE July 2017	2. REPORT TYPE Annual	3. DATES COVERED 6/30/2016-6/29/2017		
4. TITLE AND SUBTITLE Atypical Opioid Mechanisms of Control of Injury-Induced Cutaneous Pain by Delta Receptors			5a. CONTRACT NUMBER	
			5b. GRANT NUMBER W81XWH-15-1-0076	
			5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. Gregory Scherrer E-Mail: gs25@stanford.edu			5d. PROJECT NUMBER	
			5e. TASK NUMBER	
			5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Stanford University 1050 Arastradero Road, Bldg. A, Palo Alto, CA 94304-5589			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)	
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				
13. SUPPLEMENTARY NOTES				
14. ABSTRACT Severe pain due to war-related injuries is difficult to treat, and current opioids (i.e. mu opioid receptor agonists such as morphine) cause unacceptable side effects including addiction. Injuries suffered most frequently by active military personnel include traumatic brain injury, nerve trauma, skin incision, and burn injury, and all these injuries are associated with acute cutaneous pain and/or mechanical allodynia/hypersensitivity. The goals of our research are to evaluate analgesics acting on delta opioid receptors (DORs) in animal models relevant to today's battlefield experience (Specific Aim 2), and elucidate the mechanisms by which DOR agonists, administered in skin and acting on mechanosensory dorsal root ganglia neurons, relieve pain (Specific Aim 1). We have determined the analgesic effect of two DOR agonists, deltorphin II and SNC80. We show that these compounds significantly elevate mechanical pain threshold, indicating their acute antinociceptive action. Furthermore, we found that in two models of injuries, namely skin incision and nerve trauma, a single injection of deltorphin II eliminates the mechanical hyper sensitivity caused by injury. We have also initiated studies aiming at identifying the peripheral sensory neurons that express DOR, a first step towards understanding the analgesic mechanism of action of DOR agonists. We are currently extending these findings by performing the other experiments described in our original proposal, without significant change in our plans and strategy. Importantly, our promising results support our hypothesis that DOR agonists, acting in the skin, represents an effective therapeutic strategy for blocking severe pain associated with injuries that can be suffered on the battlefield.				
15. SUBJECT TERMS    Nothing listed				
16. SECURITY CLASSIFICATION OF:  a. REPORT      b. ABSTRACT      c. THIS PAGE Unclassified      Unclassified      Unclassified			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 16
			19a. NAME OF RESPONSIBLE PERSON USAMRMC	
			19b. TELEPHONE NUMBER (include area code)	

## **Table of Contents**

	<u>Page</u>
<b>1. Introduction.....</b>	<b>4</b>
<b>2. Keywords.....</b>	<b>4</b>
<b>3. Accomplishments.....</b>	<b>4</b>
<b>4. Impact.....</b>	<b>10</b>
<b>5. Changes/Problems.....</b>	<b>11</b>
<b>6. Products.....</b>	<b>12</b>
<b>7. Participants &amp; Other Collaborating Organizations.....</b>	<b>14</b>
<b>8. Special Reporting Requirements.....</b>	<b>16</b>
<b>9. Appendices.....</b>	<b>16</b>

**1. INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

This proposal will establish the mechanisms by which peripheral delta opioid receptors (DORs) inhibit mechanosensitive dorsal root ganglion (DRG) neurons, and test the hypothesis that DOR agonists can reduce pain in rodent models of injuries that soldiers can suffer on the battlefield.

**2. KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

Delta opioid receptor (DOR) agonists, cutaneous pain, acute pain, injuries suffered on the battlefield, injury-induced chronic pain, burn injury, incision injury, nerve injury, analgesia, mouse, intraplantar injections, pain behavior, electrophysiology, dorsal root ganglion neurons, histology, mechanism of action

**3. ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction.

**What were the major goals of the project?**

*List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.*

**Specific Aim 1** – To resolve the mechanism of action by which peripherally administered DOR agonists inhibit neuronal activity.

**Major Task 1:** Electrophysiological analysis

Subtask 1: To establish the effect of DOR agonists on the activity of mechanosensitive DRG neurons using a largely intact ex vivo somatosensory system preparation. Months 1-30  
Percentage of completion: 20%

*Estimated time for completing Milestone #1 Demonstration that DOR agonists inhibit action potential firing in cutaneous mechanosensitive DRG neurons: 36 months (6 months later than the 30 months originally scheduled, due to delays in obtaining approval for our animal protocol and starting these experiments.)*

**Subtask 2:** To resolve the molecular mechanisms by which DOR agonists inhibit DRG neurons in primary culture. Months 6-30

Percentage of completion: 60%

*Estimated time for completing Milestone #2 Resolution of the mechanism of action of DOR agonists: 36 months (6 months later than the 30 months originally scheduled, due to delays in obtaining the electrophysiological equipment for performing these experiments)*

**Major Task 2:** Characterization of DOR-expressing neurons in human DRG

**Subtask 1:** To characterize DOR-expressing neurons in human DRG by in situ hybridization  
Months 12-24

Percentage of completion: 10%

*Estimated time for completing Milestone #3 Demonstration that DOR expression in human DRG is similar to that observed in mouse: 36 months (12 months later than the 24 months originally scheduled, due to problems with the high endogenous fluorescence of the tissue received from NDRI (this problem is now solved) and delays in obtaining tissues from NDRI)*

**Specific Aim 2** –To test the hypothesis that peripheral administration of DOR agonists can reduce acute cutaneous pain and chronic mechanical allodynia in rodent models of injuries that soldiers can suffer on the battlefield.

**Major Task 3: Acute pain**

Subtask 1: To evaluate the utility of DOR agonists for the treatment of acute cutaneous pain.

Months 6-24

Estimated percentage of completion: 70%

*Estimated time for completing Milestone #4 Demonstration of the efficacy of DOR agonists to reduce acute pain: 24 months (no change)*

**Major Task 4: Injury-induced mechanical allodynia**

Subtask 1: To evaluate the utility of DOR agonists for the treatment of nerve trauma-induced mechanical allodynia. Months 6-30

Estimated percentage of completion: 70%

**Subtask 2:** To evaluate the utility of DOR agonists for the treatment of mechanical allodynia induced by incision injury. Months 1-24

Estimated percentage of completion: 70%

**Subtask 3:** To evaluate the utility of DOR agonists for the treatment of burn injury-induced mechanical allodynia. Months 12-36

Percentage of completion: 50%

*Estimated time for completing Milestone #5 Demonstration of the efficacy of DOR agonists to reduce injury-induced mechanical allodynia: 30 months (6 months earlier than originally the 36 months originally scheduled, as we put more effort towards Major Task 4 because we could not begin experiments for Major Tasks 1 & 2)*

**What was accomplished under these goals?**

*For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met.*


*Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.*

## **Major Task 1: Electrophysiological analysis**

Subtask 1: To establish the effect of DOR agonists on the activity of mechanosensitive DRG neurons using a largely intact ex vivo somatosensory system preparation.


Subtask 2: To resolve the molecular mechanisms by which DOR agonists inhibit DRG neurons in primary culture.

We have initiated these studies, using acutely dissociated DRG neurons. Our studies so far indicate that DORGFP+ DRG neurons are indeed mechanosensitive, consistent with our hypothesis. Thus, Figure 1 below shows that applying pressure onto DORGFP+ mice with Piezo actuator and controller induces mechanically activated currents in these cells. We are continuing these experiments to increase n and quantify these observations.



**Figure 1.** Mechanically-activated currents in DOR-expressing DRG neurons. Pressure applied on DORGFP-expressing DRG neurons induces a mechanically-activated inward currents indicating that these cells are mechanosensitive, as we hypothesized (Major Task 2, Subtask 2).

We have also started to examine the ion channel mechanisms by which DOR agonist deltorphin II may regulate the excitability of DORGFP-expressing DRG neurons. As shown in Figure 2 below, we observed a reduction in HCN channel (Hyperpolarization-activated cyclic nucleotide-gated) current when performing current-voltage (I-V) curves. This preliminary finding would suggest that DOR is coupled to HCN channels in mechanosensory DRG neurons, and that DOR agonists may diminish HCN channel opening, presumably indirectly by modulating cAMP levels.



**Figure 2.** Current-voltage (I-V) curves in the absence or presence of DOR agonist deltorphin II reveals a reduction in HCN channel (Hyperpolarization-activated cyclic nucleotide-gated) current. Left,  $\text{Na}^+$  I-V curves in the absence or presence of deltorphin II. Right, deltorphin II reduces HCN channel current density. (Major Task 2, Subtask 2).

### **Major Task 2: Characterization of DOR-expressing neurons in human DRG**

Subtask 1: To characterize DOR-expressing neurons in human DRG by *in situ* hybridization

Tissues used: human dorsal root ganglia (DRG) [National Disease Research Interchange (NDRI)] We have started these experiments. We cryoprotected DRG received from NDRI in sucrose 30%, embedded DRG in O.C.T., and froze DRG. We next sectioned DRG at 20 microns with a cryostat and applied cryosections on slides. The slides were then processed for fluorescent *in situ* hybridization with RNAscope technology (ACD Biosystems) to detect Oprd1 mRNA, as described previously for mouse DRG (Bardoni et al., *Neuron*, 2014). A number of controls were used including positive controls (Oprd1 probe on mouse tissue as done in Bardoni et al., *Neuron*, 2014) and negative controls (no probe).

Controls indicated that the technology and reagents work as expected and allow the specific detection of Oprd1 mRNA in tissues. However, as we indicated in the previous yearly report (Year 1), the controls also indicated that a high level of endogenous fluorescence was present in human DRG sensory neurons. This high level of endogenous fluorescence prevents the visualization of fluorescently labelled Oprd1 mRNA.

To circumvent this problem, we have been using a non-fluorescent *in situ* hybridization protocol. Figure 3 below shows this approach has been successful. Our results with this technique suggests that we can successfully co-label mRNA encoding TrpV1 and DOR, and that these genes are present in distinct populations of DRG neurons, as we hypothesized. Using this method, we are now resolving the molecular identity of DOR-expressing DRG neurons.




Figure 3. Detection of DOR and TrpV1 in distinct sensory neurons in human DRG (Major Task 2, Subtask 1) using a non-fluorescent *in situ* hybridization methods. Consistent with our hypothesis that DOR is expressed in large diameter mechanosensory DRG neurons, this image shows two large diameter DRG neurons expressing DOR (red dots in cytoplasm correspond to single Oprd1 mRNA molecules), surrounded by three smaller cells expressing Trpv1 (blue), which are likely C fiber nociceptors. Nuclei are counterstained in red.

#### **Major Task 4: Injury-induced mechanical allodynia**

Subtask 1: To evaluate the utility of DOR agonists for the treatment of nerve trauma-induced mechanical allodynia.


Subtask 2: To evaluate the utility of DOR agonists for the treatment of mechanical allodynia induced by incision injury.

We have initiated behavioral studies to determine whether intraplantar injection of deltorphin II can reduce the mechanical hypersensitivity resulting from injuries, including skin incision, nerve trauma, or burn. We previously reported our promising results with the skin incision model (Year 1 annual report).

We report here that deltorphin II also reduces hypersensitivity resulting from nerve trauma (Major Task 4, Subtask 1). We used the chronic constriction injury (CCI) model of nerve trauma, originally described in Bennett et al., Pain, 1988. Figure 1 below shows that this procedure caused cutaneous mechanical hypersensitivity for several days, as measured with the von Frey test. Remarkably, a single intraplantar injection of deltorphin II (10 micrograms) was sufficient to

almost completely eliminate this hypersensitivity, as soon as 20 min after the injection, and for at least 2 hours. We are presently completing these studies.

Collectively, these very encouraging data support our claim that activation of peripheral DORs is an efficient therapeutic strategy for reducing cutaneous mechanical pain that results from injuries that can be suffered on the battlefield.



**Figure 4.** Effect of the DOR agonists deltorphin II on mechanical hypersensitivity induced by nerve trauma (Major Task 4, Subtask 1). Nerve trauma (chronic constriction injury, CCI) at the level of sciatic nerve reduced mechanical pain threshold (i.e. indicating pain) compared to baseline (BL) 21 days after the injury. A single intraplantar injection of deltorphin II (10 micrograms) increased mechanical threshold and diminished pain. These results suggest that DOR activation in the periphery efficiently limits hypersensitivity resulting from nerve trauma. Data are represented as mean + SEM (error bars). Statistical analysis used a Repeated Measures ANOVA and Bonferroni posthoc test. \* indicates  $p < 0.05$ .

### What opportunities for training and professional development has the project provided?

*Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. “Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops,*

**The project was not intended to provide training and professional development opportunities. *Nothing to Report.***

**How were the results disseminated to communities of interest?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.*

**We are still collecting data to confirm our initial findings and have not yet debuted to disseminate knowledge acquired from this study. *Nothing to Report.***

**What do you plan to do during the next reporting period to accomplish the goals?**

*If this is the final report, state “Nothing to Report.”*

*Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.*

**We will be finalizing the experiments planned in Specific Aims 1 & 2, as originally described in our proposal.**

4. **IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

**What was the impact on the development of the principal discipline(s) of the project?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).*

**At this stage, our initial promising results have to be confirmed and solidified with the additional experiments and approaches, as described in our proposal, before evaluating the impact of the project on its principal discipline.**

**What was the impact on other disciplines?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.*

**Similarly, it is too early to evaluate the impact of the project on other disciplines. Nothing to Report.**

**What was the impact on technology transfer?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:*

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

**It is too early to evaluate the impact of the project on other disciplines. Nothing to Report.**

**What was the impact on society beyond science and technology?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:*

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

**It is too early to evaluate the impact of the project on society. Nothing to Report.**

**5. CHANGES/PROBLEMS:** The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:

**Changes in approach and reasons for change**

*Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.*

**We do not have any change to Report.**

**Actual or anticipated problems or delays and actions or plans to resolve the**

*Describe problems or delays encountered during the reporting period and actions or plans to resolve them.*

**We do not have any actual or anticipated problem to Report.**

**Changes that had a significant impact on expenditures**

*Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.*

**Nothing to Report.**

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

*Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.*

**Significant changes in use or care of human subjects**

*N/A*

**Significant changes in use or care of vertebrate animals.**

**Nothing to Report.**

**Significant changes in use of biohazards and/or select agents**

**6. PRODUCTS:** List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”

**• Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

**Journal publications.** *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume; year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

**We are still collecting data to confirm our initial findings and have not yet submitted any article for publication.**

**Books or other non-periodical, one-time publications.** *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: Author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

We are still collecting data to confirm our initial findings and have not yet published any book, monograph, dissertation, abstract, or the like published as or in a separate publication

**Other publications, conference papers, and presentations.** *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (\*) if presentation produced a manuscript.*

- **Website(s) or other Internet site(s)**  
*List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.*

**Nothing to report**

- **Technologies or techniques**  
*Identify technologies or techniques that resulted from the research activities. In addition to a description of the technologies or techniques, describe how they will be shared.*

**Nothing to report**

- **Inventions, patent applications, and/or licenses**  
*Identify inventions, patent applications with date, and/or licenses that have resulted from the research. State whether an application is provisional or non-provisional and indicate the application number. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.*

**Nothing to report**

- **Other Products**

*Identify any other reportable outcomes that were developed under this project.*

*Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment, and/or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:*

- *data or databases;*
- *biospecimen collections;*
- *audio or video products;*
- *software;*
- *models;*
- *educational aids or curricula;*
- *instruments or equipment;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
- *clinical interventions;*
- *new business creation; and*
- *other.*

### **Nothing to report**

## **7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

### **What individuals have worked on the project?**

*Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change.”*

<b>Name:</b>	<b>Dr. Gregory Scherrer</b>
<b>Project Role:</b>	<b>PI</b>
<i>Researcher Identifier (e.g. ORCID ID):</i>	<i>gscherrer (eRA Commons)</i>
<b>Nearest person month worked:</b>	<b>4.8</b>
<i>Contribution to Project:</i>	Dr. Scherrer has overall responsibility for the proposed research. Specifically, he designs the proposed experiments, and analyze data and interpret the results.
<i>Funding Support:</i>	<i>Department of Defense; Anesthesia Department</i>
<b>Name:</b>	<b>Amaury Francois</b>
<b>Project Role:</b>	<b>Post-Doctoral fellow</b>
<i>Researcher Identifier (e.g. ORCID ID):</i>	<i>francois.amaury (eRA Commons)</i>
<b>Nearest person month worked:</b>	<b>9</b>
<i>Contribution to Project:</i>	Dr. François performs, analyzes, and interprets in situ hybridization studies (Specific Aim 1, subaim 1.b.), and behavioral experiments (Specific Aim 2), and electrophysiological experiments in DRG

primary culture (Specific Aim 1, subaim 1.b.), Dr. François also presents the results to the research group.

*Funding Support:*

*Department of Defense; Start-up funds from Dr. Scherrer*

*Name:*

**Dr. Dong Wang**

*Project Role:*

**Research Associate**

*Researcher Identifier (e.g. ORCID ID): dong.wang2 (eRA Commons)*

*Nearest person month worked:* **12**

*Contribution to Project:* Histological and behavioral experiments

*Funding Support:*

*Department of Defense; Anesthesia Department*

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

**Nothing to report**

What other organizations were involved as partners?

*Nothing to Report*

## **8. SPECIAL REPORTING REQUIREMENTS**

**COLLABORATIVE AWARDS:** N/A

**QUAD CHARTS:** N/A

## **9. APPENDICES:** N/A